Recruiting Clinical Trials

Displaying 71 - 80 of 242 result(s)
Study Title Condition Phase Location
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal Neovascular Age-related Macular Degeneration (nAMD) Not Given
  • Country: 
    Portugal
An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With ... Paroxysmal Nocturnal Hemoglobinuria Phase 3
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    More locations
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies Phase 2
  • Country: 
    Singapore
  • Country: 
    Spain
  • Country: 
    Taiwan
Brolucizumab Treatment Experience Study of Patients With Neovascular Age-related Macular Degeneration (nAMD) in UK Routine Clinical Practice (BESRA) Neovascular Age-related Macular Degeneration Not Given
  • Country: 
    United Kingdom
A Descriptive Study of PIK3CA Mutations and Outcomes With Alpelisib in Patients With HR-positive and HER2-negative Advanced Breast Cancer (ABC)/ Metastatic Breast Cancer (MBC) in India Breast Cancer Not Given
  • Country: 
    India
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study Multiple Sclerosis Not Given
  • Country: 
    United States
A Two-part, Randomized, Investigator- and Participant- Blinded, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MHS552 in Adult Participants With Systemic Lupus Erythemato ... Lupus Erythematosus, Systemic Phase 1
  • Country: 
    Germany
A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Systemic Pharmacokinetics of Icenticaftor in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants Hepatic Failure Phase 1
  • Country: 
    United States
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors Solid Tumors Phase 1
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    Hong Kong
  • Country: 
    More locations
An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants Cryptosporidium Infection, Cryptosporidiosis Phase 1
  • Country: 
    United States